COVID-19肺炎幸存者5年定量CT与超极化氙MRI随访
本研究对COVID-19肺炎幸存者进行5年前瞻性随访,联合纵向胸部CT、吸呼气定量CT、肺功能及超极化氙129通气MRI评估。5年时35.6%幸存者仍存在残留病变,25.5%存在弥散功能异常,2至5年间CT异常及肺功能无显著变化。
要点
- 5年时幸存者通气缺损百分比及功能性小气道疾病定量指标仍高于健康对照,重度肺炎组异常更显著。
- 报告5年随访CT时,残留病变需结合弥散功能及通气MRI结果综合解读,单纯CT稳定不代表功能完全恢复。
核心结论
- 5年时部分COVID-19肺炎幸存者仍存在呼吸道症状、弥散功能异常及通气缺损,但肺功能与CT异常在2至5年间保持稳定。
研究设计与样本
- 前瞻性纵向研究,纳入143名受试者(平均年龄62±11.0岁;74名男性),其中83例重度、21例非重度COVID-19肺炎幸存者及39名年龄性别BMI匹配的健康对照。
- 幸存者在急性期、6个月、1年、2年及5年完成系列胸部CT;5年时增加吸呼气定量CT、肺功能、症状评估及超极化氙129通气MRI。
- 采用协变量校正的线性回归模型比较对照组与两组幸存者的定量CT及通气参数,并以校正回归模型确定其与肺功能和症状的关联。
关键影像表现/征象
- 5年随访时35.6%(104例中37例)的幸存者胸部CT仍见残留病变。
- 5年随访时25.5%(102例中26例)的幸存者仍存在弥散功能异常。
临床应用与阅片要点
- 5年随访阅片时,CT所见残留病变的稳定不代表肺功能恢复,需结合弥散功能与通气MRI评估。
- 重度COVID-19肺炎幸存者的小气道功能异常更突出,定量CT参数响应图指标有助于识别持续性功能损害。
- 对于5年随访仍存在弥散功能异常的病例,常规CT无新发现时仍应建议功能影像进一步评估。
局限性
- 研究匹配的对照组样本量较小(39名),可能影响组间比较的统计效能。
- 非重度COVID-19肺炎幸存者仅21例,该亚组的结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Whether pulmonary sequelae persist 5 years after COVID-19 pneumonia remains unknown. Purpose To evaluate 5-year pulmonary abnormalities in survivors of COVID-19 pneumonia with use of longitudinal chest CT, inspiratory-expiratory quantitative CT, pulmonary function testing, and hyperpolarized xenon 129 (129Xe) ventilation MRI and to compare findings with those in matched healthy controls. Materials and Methods This prospective longitudinal study performed a 5-year follow-up from September to December 2025, enrolling survivors of severe and nonsevere COVID-19 pneumonia along with age-, sex-, and body mass index-matched healthy controls. Survivors underwent serial chest CT during the acute phase and at 6-month, 1-year, 2-year, and 5-year follow-ups. At 5 years, participants underwent inspiratory-expiratory CT, pulmonary function testing, symptom assessment, and hyperpolarized 129Xe ventilation MRI. Quantitative CT and ventilation parameters were compared among controls and both survivor groups with use of covariate-adjusted linear regression models, and associations of these parameters with pulmonary function and symptoms were determined with adjusted regression models. Results This study included 143 participants (mean age, 62 years ± 11.0 [SD]; 74 male; 83 survivors of severe COVID-19 pneumonia, 21 survivors of nonsevere COVID-19 pneumonia, and 39 healthy controls). After 5 years, residual lesions persisted in 35.6% of survivors (37 of 104), and abnormal diffusing capacity remained present in 25.5% (26 of 102). Prespecified comparison between 2- and 5-year follow-ups showed no evidence of change in respiratory symptoms (all P ≥ .88), pulmonary function (all P ≥ .67), or conventional CT abnormalities (all P ≥ .81) among survivors. At 5 years, ventilation defect percentage as well as parametric response mapping measures of functional small airway disease and emphysema differed among controls and both survivor groups (all P ≤ .01), with greater abnormalities generally observed in survivors of severe COVID-19 pneumonia (all P ≤ .005 vs controls). Conclusion Five years after COVID-19 pneumonia, some survivors showed persistent respiratory symptoms, abnormal diffusion capacity, and ventilation defects, with stable pulmonary function and no change in CT abnormalities between 2 and 5 years. Clinical trial registration no. ChiCTR2000038609 © RSNA, 2026 Supplemental material is available for this article.
引用
- Han, Guo, Fan, et al. Five-year Quantitative Chest CT and Hyperpolarized Xenon 129 Ventilation MRI Findings in Survivors of COVID-19 Pneumonia. Radiology. 2026. PMID: 42770821. doi:10.1148/radiol.261153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。